MN HF2527

Renames the "Controlled Substances Prescription Electronic Reporting System" to "Prescription Monitoring Program" throughout statute 152.126.

Expands controlled substances subject to reporting to include tramadol and butalbital, and allows prescribers authorized under section 152.12, subdivision 2 to access the system.

Modifies data retention requirements: data available to permissible users for 12 months from receipt, with de-identified data retained up to 5 years; allows board personnel and vendors to retain all collected data for program administration, trend analysis, and program evaluation.

Changes exemptions from reporting to include only drugs distributed through automated systems in health care facilities and manufacturer-packaged drug samples, removing previous exemptions for nursing facilities, assisted living, intravenous medications, and hospice care.

Requires Board of Pharmacy to report to legislature by December 15, 2014 on whether to mandate prescription monitoring program database use by prescribers and pharmacists, impacts on drug abuse rates, and recommendations for treatment access approaches.